Erdafitinib launch date

Erdafitinib(Erdafitinib) was approved for marketing by the U.S. FDA on 2019 4month12. Erdafitinib(Erdafitinib) is a multikinase inhibitor. Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) who are susceptible to FGFR3 or span>FGFR2gene alteration that has progressed during or after at least one prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

Sometimes it is unsafe to use certain drugs together. Some medicines can affect the blood levels of other medicines you use, which may increase side effects or make the medicine less effective. Tell your doctor about all other drugs, especially drugs that may change phosphate levels-Potassium phosphate supplements, vitaminDsupplements, antacids, enemas, or laxatives containing phosphates, and other drugs known to contain phosphates. Other drugs may affect erdafitinib, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all the medicines you currently take and any medicines you start or stop using. Erdafitinib(Erdafitinib)The most common adverse reactions, including laboratory abnormalities(≥20%), include increased phosphate, stomatitis, fatigue, increased creatinine, diarrhea, dry mouth, and nail abnormalities. Common, increased alanine aminotransferase, increased alkaline phosphatase, decreased sodium, decreased appetite, decreased albumin, dysgeusia, decreased hemoglobin, dry skin, increased aspartate aminotransferase, decreased magnesium, dry eyes, alopecia, palmar paresthesia syndrome, constipation, decreased phosphate, abdominal pain, increased calcium, nausea, and musculoskeletal pain. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.